A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Reviewed by David Kindness Fact checked by Suzanne Kvilhaug What Are Key Financial Ratios for Pharma? Pharmaceutical ...

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% ...

pharmaceuticals are unlikely to de-globalise or shift heavily toward regional production. Instead, companies are embracing growth strategies, such as mergers, acquisitions, and asset swaps.

Partex's platform will provide comprehensive analyses, including target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative ...

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating ...